FDA Reclassifies VHP to Category A: What It Means for Medical Device Manufacturers

On January 24, 2024, the FDA issued a press announcement formally reclassifying vaporized hydrogen peroxide (VHP) sterilization to Established Category A. The announcement was brief. Its regulatory implications were substantial — and have grown more consequential in the months since.

This article explains what Category A designation means, how it works alongside ISO 22441:2022, what changed for different types of manufacturers, and what remained the same.

The Three-Category Framework and What Category A Actually Means

FDA's categorization of sterilization methods provides a structured framework for how manufacturers present sterilization information in premarket submissions. The framework has three tiers:

Established Category A — Methods with an extensive, well-characterized body of published scientific evidence, validated biological indicator systems, and established international consensus standards. The FDA review process for Category A submissions focuses on process validation documentation, not on justification that the method itself is appropriate. Steam (ISO 17665), ethylene oxide (ISO 11135), dry heat (ISO 20857), radiation (ISO 11137), and — as of January 2024 — vaporized hydrogen peroxide (ISO 22441) occupy Category A.

Established Category B — Methods with a developing evidence base and regulatory precedent but lacking the full scientific foundation and standardization infrastructure of Category A. Before January 2024, VHP occupied Category B. Nitrogen dioxide (NO₂) is the current prominent Category B method. Category B submissions require more extensive justification of method suitability, and FDA review carries more inherent uncertainty about outcome.

Novel Category — Methods without established regulatory history or international consensus standards. Submissions using novel methods require the highest evidentiary burden and are subject to the most variable review timelines.

VHP's move from Category B to Category A is not a procedural reclassification. It reflects FDA's determination that the accumulated body of VHP sterilization science — the published microbial inactivation studies, the material compatibility databases, the biological indicator characterization work, and the ISO 22441:2022 standard itself — meets the evidentiary standard that defines established methods. That determination changes the submission dynamic in a specific and consequential way.

How the Submission Dynamic Changed

Under Category B, a manufacturer submitting a 510(k) for a VHP-sterilized device was required to provide a sterilization justification — documentation explaining why VHP was appropriate for the specific device, how it compared to established methods, and why the manufacturer had selected a non-established method. This justification section added documentation burden, created potential review questions around method equivalence, and introduced the possibility of FDA requests for additional data that did not arise in EtO or steam submissions.

Under Category A, that justification requirement is eliminated. A 510(k) sterility section for a VHP-sterilized device now follows the same structure as a steam, EtO, or irradiation submission: identify the sterilization method, cite the applicable Category A designation and standard, present the process validation documentation, and confirm SAL 10⁻⁶ achievement with biological indicator data, material compatibility assessment, and residue characterization.

FDA's updated sterilization guidance for 510(k) submissions specifies the documentation requirements for Category A submissions. The sterility section must include: identification of the sterilization method and the applicable standard (ISO 22441 for VHP); a summary of the validation approach and results; evidence of SAL 10⁻⁶ achievement; material compatibility assessment; and residue risk assessment. Each of these elements is produced by the ISO 22441 validation lifecycle — process development, IQ, OQ, PQ, and residue testing. There is no new documentation category that VHP requires beyond what an established sterilization submission already contains.

ISO 22441:2022 — The Companion Standard

Category A status and ISO 22441 function together. The Category A designation establishes the evidentiary foundation. ISO 22441 defines the technical execution framework.

ISO 22441:2022, "Sterilization of health care products — Low temperature vaporized hydrogen peroxide" was published in 2022 and recognized by FDA as a consensus standard in May 2023 — seven months before the Category A reclassification. It provides the complete framework for VHP sterilization process development, installation qualification, operational qualification, performance qualification, and routine control.

The standard is structured to parallel ISO 11135 (EtO) and ISO 11137 (radiation) — the standards that EtO and irradiation manufacturers have used for decades. The process development phase (Section 5.2) addresses biological indicator selection, D-value characterization, and cycle parameter development. The validation phases (Sections 5.3–5.4) define IQ, OQ, and PQ requirements. The performance qualification specifies the half-cycle method with *Geobacillus stearothermophilus* as the reference biological indicator organism. Section 5.4.5 addresses residue assessment.

For manufacturers with EtO or irradiation validation experience, ISO 22441 is immediately navigable — it uses the same validation architecture and the same IQ/OQ/PQ lifecycle framework. The critical parameters are different (VHP concentration, temperature, humidity, and aeration vs. EtO concentration, temperature, humidity, and time), and the biological indicator organism is different (G. stearothermophilus rather than B. atrophaeus for EtO), but the structural logic of the validation is identical.

What Changed for Different Manufacturer Types

**Small and mid-size device manufacturers** gain the most direct benefit. Before Category A, the sterilization justification requirement created a regulatory uncertainty premium — a risk that FDA might request additional information, extend review timelines, or raise questions about method equivalence that would not arise for EtO submissions. Category A eliminated that premium. The predictability of VHP submissions is now equivalent to EtO or irradiation submissions, which affects how development programs are planned, how regulatory timelines are modeled, and how investors evaluate programs with VHP-sterilized device components.

Combination product manufacturers — companies developing devices with pharmaceutical or biologic coatings — benefit from a different dimension of the change. Many combination products cannot tolerate EtO residue (which interacts with protein and drug components) or gamma irradiation (which degrades drug and biologic constituents). Before Category A, the submission for a combination product sterilized by VHP required justifying the method choice against EtO and irradiation, adding regulatory complexity to an already complex product category. Category A means the VHP choice is the natural, established-method selection — not an alternative requiring justification.

**Tissue banks and tissue processors** operate under FDA CGTP (21 CFR Part 1271) and AATB Standards rather than 510(k)/PMA, but the regulatory significance of Category A extends to tissue applications through the same mechanism — FDA's recognition that VHP is an established sterilization method with a characterized evidence base. Tissue banks validating VHP sterilization under ISO 22441 are aligning with a recognized framework that AATB auditors and FDA CGTP inspectors can assess against published standards.

**Contract sterilizers** adding VHP capability to serve device manufacturer customers benefit from the submission environment Category A creates for those customers. A contract sterilizer offering VHP services to a manufacturer filing a 510(k) is offering a service whose regulatory pathway is fully defined. The manufacturer's submission will not be delayed by sterilization method uncertainty, and the contract relationship is not encumbered by the regulatory risk that Category B submissions carried.

What Did Not Change

Category A recognition is a regulatory designation, not a validation shortcut. The technical requirements for demonstrating that a VHP sterilization process achieves SAL 10⁻⁶ are unchanged.

Manufacturers still execute the full ISO 22441 validation lifecycle: process development, material compatibility assessment, IQ, OQ, PQ with biological indicator challenges, residue assessment, and documentation compilation. Three consecutive PQ runs achieving zero growth in *G. stearothermophilus* biological indicators at worst-case chamber positions remain the performance standard. Ongoing monitoring — biological indicator testing at defined intervals, parametric release, periodic requalification — remains required as a condition of maintaining a validated process.

The reclassification changed how FDA reviewers approach VHP submissions. It did not change what validated VHP sterilization requires. Manufacturers who approach Category A recognition as permission to reduce validation rigor will produce documentation packages that do not withstand FDA review — precisely because Category A subjects VHP submissions to the same evidentiary scrutiny applied to every other established method.

The Convergence That Made Category A Possible

Category A recognition did not happen because FDA decided to be more accommodating about VHP. It happened because the accumulation of scientific evidence met the evidentiary standard the category requires. Understanding that accumulation helps explain why the reclassification was appropriate and what it signals about VHP's technical position.

The published evidence base for VHP sterilization covers three decades of applied validation work. It includes material compatibility data across thousands of polymer, metal, and composite combinations. It includes biological indicator characterization work that established D-values for *G. stearothermophilus* under VHP exposure conditions with the specificity necessary for half-cycle method PQ design. It includes process development studies across product categories from medical implants to biological tissue to combination products. And it includes the ISO 22441 standard itself — which represents the consensus of international sterilization science experts on how VHP processes should be developed, validated, and controlled.

That body of evidence is what FDA evaluated in determining that VHP meets the Category A standard. The reclassification is a regulatory recognition of scientific completeness — not a policy decision or a market accommodation.

Frequently Asked Questions

**What is the practical difference between a Category A and a Category B sterilization submission?**

A Category A submission identifies the sterilization method, cites the applicable standard and Category A designation, and presents process validation documentation. FDA review assesses the quality and completeness of the validation. A Category B submission must additionally justify that the chosen method is appropriate for the specific device — explaining why it was selected over established alternatives and demonstrating equivalence or superiority. This additional justification step creates documentation burden, potential review questions, and timeline uncertainty that Category A submissions do not carry.

**Does Category A recognition mean VHP validation is simpler than EtO or steam validation?**

No. Category A means the regulatory submission pathway is equivalent in complexity to EtO or steam — not that the underlying validation is simpler. The ISO 22441 validation lifecycle includes process development, material compatibility assessment, IQ/OQ/PQ execution, biological indicator qualification, residue assessment, and ongoing monitoring — the same categories of validation work required for any established sterilization method. What Category A eliminates is the method justification requirement in the submission, not any component of the validation itself.

**What is ISO 22441 and do I need it to use VHP in a 510(k) submission?**

ISO 22441:2022 is the international standard for low-temperature vaporized hydrogen peroxide sterilization of health care products. It defines the technical requirements for process development, installation qualification, operational qualification, performance qualification, and routine control. FDA recognized it as a consensus standard in May 2023. Using ISO 22441 as the validation framework for a VHP sterilization process is the established approach for Category A submissions — it provides the documented technical foundation that FDA's sterility review requires. Manufacturers can submit under FDA's general sterilization guidance without ISO 22441, but the ISO 22441 framework is the recognized standard and the most efficient path through FDA review.

**Does Category A recognition apply to tissue banks and tissue processors, or only device manufacturers?**

The Category A designation applies to FDA's framework for medical device sterilization submissions (510(k)/PMA). Tissue banks and processors operate under FDA CGTP (21 CFR Part 1271) and AATB Standards, which have their own sterilization validation requirements. However, Category A recognition and ISO 22441 carry regulatory weight for tissue applications by establishing VHP as a scientifically established, internationally standardized method — one that AATB auditors and FDA CGTP inspectors assess against published technical standards rather than case-by-case justification. Tissue banks validating VHP sterilization per ISO 22441 are using the same framework that FDA recognizes for device applications.

**What biological indicator is used in VHP sterilization validation, and why?**

ISO 22441:2022 specifies *Geobacillus stearothermophilus* as the reference biological indicator organism for VHP sterilization validation. G. stearothermophilus spores are selected for their resistance to hydrogen peroxide — they are the hardest-to-kill organism relevant to VHP sterilization conditions, making them the appropriate worst-case challenge organism for half-cycle method performance qualification. G. stearothermophilus is the same organism used in steam sterilization validation, meaning manufacturers with steam sterilization experience are already familiar with the organism's characterization methodology and the half-cycle PQ approach. Biological indicators for VHP validation are commercially available from established suppliers with published D-values specific to VHP exposure conditions.